// App-Quantinova.ai

TP1371 : Efficacy of omalizumab in hereditary alpha tryptasaemia

Researchers

Presenter

  • Dziadzio M

Principal Investigators

  • Briggs T

  • Rutkowski C

  • Grattan CE

  • Wilcock A

  • Robey R

  • Kariyawasam H

  • Robinson D

  • Arkwright PD

Medical Centers

  • NCRI, London, United Kingdom

  • Manchester Centre for Genomic Medicine, St. Mary's Hospital and Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, United Kingdom

  • Urticaria Clinic, Specialist Ambulatory Services, St John's Institute of Dermatology, Guy's and St. Thomas’ Hospital NHS Foundation Trust, London, United Kingdom

  • Manchester Centre for Genomic Medicine, Manchester, United Kingdom

  • Manchester Centre for Genomic Medicine, Royal Manchester Children's Hospital, Manchester, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • Immunoglobulin E

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

  • Tryptase Alpha/Beta 1

Drug/Treatment

  • Prednisolone

  • Montelukast

  • Omalizumab

  • histamine

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved